Small Molecules
15 September 2015
AZTherapies Commences Phase III Pivotal Trial – for ALZT-OP1 in Early Alzheimer’s Disease15 September 2015
XenoPort Announces Positive Phase 2 Study Results for XP23829 as a Potential Treatment for Patients with Psoriasis15 September 2015
FORUM Pharmaceuticals Inc. Updates Encenicline Phase 3 Clinical Trial Programs in Alzheimer’s Disease and Cognitive Impairment in Schizophrenia14 September 2015
Raptor Pharmaceutical Provides Topline Results From Phase 2b CyNCh Study Evaluating RP103 in Pediatric Nonalcoholic Steatohepatitis14 September 2015
Laguna Pharmaceuticals Initiates Phase 3 Study of Vanoxerine in Atrial Fibrillation and Atrial Flutter14 September 2015
Theravance Biopharma and Mylan Initiate Phase 3 Program for Revefenacin (TD-4208) for Treatment of Chronic Obstructive Pulmonary Disease (COPD)14 September 2015
IMBRUVICA® (ibrutinib) Supplemental New Drug Application for Treatment-naive Chronic Lymphocytic Leukemia Submitted to the U.S. FDA12 September 2015
Collegium Announces FDA Advisory Committees Unanimously Recommend Approval of Xtampza ER(TM), an Abuse-Deterrent Analgesic for Chronic Pain11 September 2015
Summit Therapeutics Completes Targeted Enrolment for SMT19969 Phase 2 Trial for C. difficile Infection11 September 2015
Skin Disposition Study Results for Dermira’s DRM01 Program in Acne Presented at International Dermatology Meeting11 September 2015
Theravance Biopharma Presents Positive Clinical Data on Fixed-Dose Combination (FDC) of Axelopran (TD-1211) and Oxycodone at PAINWeek(R) 201511 September 2015
Blueprint Medicines Receives FDA Authorization to Advance Novel Drug Candidate into Clinical Trial for Systemic Mastocytosis11 September 2015
Medicure Announces Filing of sNDA for New AGGRASTAT® Indication11 September 2015
Trevi Therapeutics Announces Positive Results from Phase 2/3 Trial in Uremic Pruritus11 September 2015
Merck Intends to Submit Cladribine Tablets to Treat Multiple Sclerosis for Registration in Europe10 September 2015
GenSpera Announces Encouraging Interim Phase II Data for Glioblastoma, Showcases Positive Future for Mipsagargin Across Multiple Types of Solid Tumors10 September 2015
Cara Therapeutics Initiates Phase 3 Program for I.V. CR845 in Acute Postoperative Pain10 September 2015
AcelRx Pharmaceuticals’ ARX-04 Meets all Endpoints in Pivotal Phase 3 Study for Moderate-to-Severe Acute Pain10 September 2015
MGCD265 demonstrates clinical efficacy with confirmed responses in NSCLC patients with Met and Axl gene amplification10 September 2015
BIND Therapeutics Initiates Multicenter iNSITE 2 Trial with BIND-014 in Four Tumor Histologies9 September 2015
Tetraphase Announces Top-Line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in cUTI9 September 2015
Flexion Therapeutics Reports Top-Line Data From Pivotal Phase 2b Clinical Trial for FX0069 September 2015
AstraZeneca Presents Further Evidence for the Potential of AZD9291 in First-Line and Pre-Treated Non-Small Cell Lung Cancer9 September 2015
Genkyotex Announces Top-Line Results of Phase 2 Clinical Program9 September 2015
Chugai’s ALK Inhibitor “Alectinib,” New Drug Application Submitted for ALK Positive Advanced Non-Small Cell Lung Cancer in the United StatesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports